Invion Ltd
ASX:IVX

Watchlist Manager
Invion Ltd Logo
Invion Ltd
ASX:IVX
Watchlist
Price: 0.097 AUD -3% Market Closed
Market Cap: 8.2m AUD

EV/EBITDA
Enterprise Value to EBITDA

-1.1
Current
-23.8
Median
13.3
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-1.1
=
Enterprise Value
7.5m AUD
/
EBITDA
-6.8m AUD
EBITDA Growth EV/EBITDA to Growth
AU
Invion Ltd
ASX:IVX
Average EV/EBITDA: 437
Negative Multiple: -1.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.6
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10
5%
2
UK
AstraZeneca PLC
LSE:AZN
131.1
10%
13.1
US
Merck & Co Inc
NYSE:MRK
9
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
292.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A